GlobeNewswire Inc.··NaNovo Nordisk Licenses Vivtex Technology for Oral Obesity and Diabetes Treatments
Novo Nordisk licenses Vivtex's oral drug-delivery technology for obesity and diabetes treatments, with potential $2.1B in milestone payments to develop oral alternatives to injectable biologics.
NVOpartnershipobesity treatment